

EQIC OPIOID “ROADE” WORK

Reducing Opioid Adverse Drug Events

Kickoff webinar

July 27, 2021



EQIC

EASTERN US QUALITY
IMPROVEMENT COLLABORATIVE


Objectives/Agenda




- Describe the importance of the opioid crisis and understand the nationwide statistics
- Discuss the EQIC approach to reducing opioid prescribing and ADEs
- Prepare the hospitals to evaluate current state and develop an action plan

Understanding the statistics

Overdose death rates by opioid type



Monthly drug overdose deaths




93,331 reported deaths from overdoses in 2020, up from 70,980 the year before, marking the largest annual increase in at least 50 years.

Note: Synthetic opioid deaths exclude those from methadone. Specific drug-class deaths are not mutually exclusive.

Data: Final 2016–2019 monthly totals: CDC WONDER; Estimated 2020 monthly totals: Calculations based on National Vital Statistics System [Provisional Drug Overdose Death Counts](#), CDC WONDER.

Source: Jesse C. Baumgartner and David C. Radley, "The Spike in Drug Overdose Deaths During the COVID-19 Pandemic and Policy Options to Move Forward," *To the Point* (blog), Mar. 25, 2021. <https://doi.org/10.26099/gyf5-3z49>


Opioid overdose deaths by race/ethnicity



KFF analysis of Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Multiple Cause of Death 1999-2019 on CDC WONDER Online Database, released 2021. Data are from the Multiple Cause of Death Files, 1999-2019, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at <http://wonder.cdc.gov/mcd-icd10.html> on February 26, 2021.

Drug overdose deaths by jurisdiction

Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: November 2019 to November 2020



Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods



Select predicted or reported number of deaths


- ☒ Predicted
- ☐ Reported

Percent Change for United States

29.4



Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: December 2019 to December 2020



New York
 Predicted cases, December 2020: 3,000
 Predicted cases, December 2019: 2,267
 Percent change: 32.3
 * Underreported due to incomplete data.


29.4



Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods



Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: December 2019 to December 2020



Connecticut
 Predicted cases, December 2020: 1,385
 Predicted cases, December 2019: 1,251
 Percent change: 10.7
 * Underreported due to incomplete data.

29.4



Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods




Drug overdose deaths: EQIC partner states

Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction:
December 2019 to December 2020

Select predicted
or reported
number of deaths

- ☒ Predicted
☐ Reported




Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods



Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction:
December 2019 to December 2020

Select predicted
or reported
number of deaths

- ☒ Predicted
☐ Reported




Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods



Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction:
December 2019 to December 2020

Select predicted
or reported
number of deaths

- ☒ Predicted
☐ Reported




Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods



Figure 1b. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction:
December 2019 to December 2020

Select predicted
or reported
number of deaths

- ☒ Predicted
☐ Reported



Legend for Percent Change in Drug Overdose Deaths Between 12-Month Ending Periods



Real life story

Travis N. Rieder, PhD



- Johns Hopkins Berman Institute of Bioethics
 - Assistant Director for Education Initiatives
 - Director of the Master of Bioethics degree program and Research Scholar
- Johns Hopkins School of Public Health
 - Faculty Affiliate at the Center for Public Health Advocacy
 - Additional info
 - <https://www.aamc.org/news-insights/bioethicist-s-personal-opioid-nightmare>

Real life story



https://www.ted.com/talks/travis_rieder_the_agony_of_opioid_withdrawal_and_what_doctors_should_tell_patients_about_it

EQIC's approach to reducing opioid prescribing and ADEs

EQIC's approach



- Monitoring and analyzing data to better understand and respond to the opioid epidemic
- Supporting hospitals across multiple states by providing hands-on support
- Providing resources and evidence-based strategies
- Providing SME support

EQIC opioid sprint



- Six webinars from July 2021 - Feb 2022
- National experts in best practices
- Improvement activity for hospitals between webinars
- PM support throughout the sprint

Syllabus



ROADE Work Syllabus

To register for the webinars, visit the [EQIC Events page](#).

For questions related to this content or to join the opioids listserv, please contact Aashna Taneja (ataneja@hanys.org) or Lindsay Milchtein (lmilchte@hanys.org).

EQIC is pleased to offer *ROADE Work*, a comprehensive and strategic approach in our opioid adverse drug event initiative.

Our CMS goals are to reduce ADEs related to opioids by 7% and opioid overprescribing by 12% over the course of the four-year EQIC program. These are tough goals, but critically important to addressing the opioid epidemic.

EQIC opioid sprint programming outline

Webinar 2: Opioid prescribing guidelines and best practices

Subject matter expert: Matthew Jared, MD

September 28, 2021

1-2pm EST

- Best practices and guidelines for prescribing opioids
- Strategies for dosing, tapering, dual ordering and avoiding co prescribing
- Exceptions to opioid “rules” for cancer, palliative and hospice patients
- Care team support workflows to reduce opioid related errors
- Pharmacist’s roles in care team and in opioid management

EQIC opioid sprint programming outline

Webinar 3: Opioid adverse drug events, pain management and opioid alternatives

Subject matter expert: Matthew Jared, MD

October 26, 2021

1-2pm EST

- Best practices for preventing opioid ADEs
- Screening tools to identify patients at risk for opioid ADEs
- Patient monitoring protocols and tools
- Strategies for managing opioid related complications and side effects
- Compare and contrast the alternatives to opioids for pain management

EQIC opioid sprint programming outline

Webinar 4: Targeted areas for improvement (emergency department, operating room, transitions of care)

Subject matter experts: Jennifer Waljee, M.D., M.P.H., M.S. and Joshua J. Lynch DO, EMT-P, FAAEM, FACEP

November 30, 2021

1-2pm EST

- Workflows for opioid prescribing in the emergency department
- Strategies for preoperative screening and post-operative prescribing
- Considerations for outpatient discharge planning
- Transitions of care best practices

EQIC opioid sprint programming outline

Webinar 5: Discharge Planning, Patient and Family engagement and Stigma

Subject matter expert: TBD

January 25, 2022

1-2pm EST

- Best practices for discharge transitions including Medication Assisted Treatment (MAT), CBOs and Behavioral Health treatment
- Best practices for Patient and Family Engagement
- Stigma towards opioids and understand approaches to address it

EQIC opioid sprint programming outline

Webinar 6: Capstone

February 22, 2022, 1-2pm EST

- Hospital successes
- Learnings and ongoing challenges
- Next steps

EQIC opioid measures



- Opioid reversal agent use
- Narcan co-order with opioid at discharge
- Opioid mortality Fee for Service
- Opioid mortality All payer
- Inpatient opioid dosing
- High-dose opioid prescribing upon discharge
- Concurrent opioid and benzodiazepine prescriptions
- Concurrent opioid and benzodiazepine prescriptions at discharge
- Co-prescribing opioids during hospitalizations
- Co-prescribing opioids at discharge
- Opioid ADE













Develop an action plan

EQIC Gap Analysis Tool

Adverse Drug Event Gap Analysis for Opioids



The following checklist assesses a hospital's compliance with best practice strategies to reduce opioid-related adverse drug events.

EVIDENCE-BASED BEST PRACTICE FOR OPIOIDS	IMPLEMENTATION STATUS			ACTION PLAN/NEXT STEPS List specific activities your team will seek to accomplish to fully implement each practice recommendation.
	FULLY	PARTIALLY	NONE	
HOSPITAL LEADERSHIP AND OVERSIGHT				
Hospital has a leader or leadership team that is responsible for safe opioid prescribing and development and monitoring of performance improvement activities related to opioids.				
Hospital routinely tracks and trends opioid usage and ADE data and information.				
Hospital routinely provides departments and physicians with opioid usage data and information such as: <ul style="list-style-type: none">• referrals to medication-assisted treatment;• percent of patients discharged on opioids with Narcan prescriptions;• percent of patients with 90 MME or greater dosing;• percent of patients on co-occurring benzodiazepines; and• percent of patients on two or more opioids simultaneously.				
PATIENT RISK ASSESSMENT				
Standardized assessments are utilized throughout the hospital to assess the patient's: <ul style="list-style-type: none">• opioid status (naïve v. tolerant);• respiratory risk factors;				

EQIC Discovery Tool



Discovery Tool: Opioid Adverse Drug Events

In the section below, please enter "y" or "n" for patient being tracked to indicate if the following elements were completed. Note: All fields must be filled in.

Dates being tracked: Please enter the current period being tracked here:

Element	Best Practice	Patient Sample														
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Patient ID# (optional)		ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE	ID# HERE
Upon admission	Patient is screened using an opioid risk assessment tool															
	Patient is screened for opioid addiction and protocol is implemented to treat patients as needed															
	Patient's opioid status (naïve vs. tolerant) is documented in the health record or prescriber orders															

▶

Opioid ADE

(+)

⋮

◀

Workgroup



- Multidisciplinary team
 - Nursing, pharmacist, physician champion, PFE leads, care management, ED, OR
- Data analysis
- Process improvement tools and methodology
 - PDSA
 - RCA
- Staff training

Next steps

- Reach out to your PMs to:
 - Complete optional current assessment and gap analysis tools to better understand the infrastructure and best practices in place
 - Organize ADE teams or opioid workgroups
 - Schedule regular workgroup meetings
 - Assess data analysis and reporting
- Enroll in the “ADE Opioid” Listserv
- Register for the upcoming webinars

Thank you.

Aashna Taneja

ataneja@hanys.org

Lindsay Milchteim

lmilchte@hanys.org



EQIC

EASTERN US QUALITY
IMPROVEMENT COLLABORATIVE